The Muonium Atom as a Probe of Physics beyond the Standard Model

The observed interactions between particles are not fully explained in the successful theoretical description of the standard model to date. Due to the close confinement of the bound state muonium ($M = \mu^+ e^-$) can be used as an ideal probe of quantum electrodynamics and weak interaction and also for a search for additional interactions between leptons. Of special interest is the lepton number violating process of sponteanous conversion of muonium to antimuonium.Comment: 15 pages,6 figure

Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer

We evaluated ancestry effects on mutation rates, DNA methylation, and mRNA and miRNA expression among 10,678 patients across 33 cancer types from The Cancer Genome Atlas. We demonstrated that cancer subtypes and ancestry-related technical artifacts are important confounders that have been insufficiently accounted for. Once accounted for, ancestry-associated differences spanned all molecular features and hundreds of genes. Biologically significant differences were usually tissue specific but not specific to cancer. However, admixture and pathway analyses suggested some of these differences are causally related to cancer. Specific findings included increased FBXW7 mutations in patients of African origin, decreased VHL and PBRM1 mutations in renal cancer patients of African origin, and decreased immune activity in bladder cancer patients of East Asian origin

Search for black holes and other new phenomena in high-multiplicity final states in proton-proton collisions at root s=13 TeV

Peer reviewe

Collider aspects of flavour physics at high Q

This review presents flavour related issues in the production and decays of heavy states at LHC, both from the experimental side and from the theoretical side. We review top quark physics and discuss flavour aspects of several extensions of the Standard Model, such as supersymmetry, little Higgs model or models with extra dimensions. This includes discovery aspects as well as measurement of several properties of these heavy states. We also present public available computational tools related to this topic.Comment: Report of Working Group 1 of the CERN Workshop ``Flavour in the era of the LHC'', Geneva, Switzerland, November 2005 -- March 200

Search for a heavy bottom-like quark in pp collisions at √s =7 TeV

This is the Pre-Print version of the Article. The official published version of the paper can be accessed from the link below - Copyright @ 2011 Elsevier.A search for pair-produced bottom-like quarks in pp collisions at sqrt(s) = 7 TeV is conducted with the CMS experiment at the LHC. The decay b' to tW is considered in this search. The b' b'-bar to tW^- t-bar W^+ process can be identified by the distinctive signature of trileptons and same-sign dileptons. With a data sample corresponding to an integrated luminosity of 34 inverse picobarns, no excess above the standard model background predictions is observed and a b' quark with a mass between 255 and 361 GeV/c^2 is excluded at the 95% confidence level.This work is supported by the FMSR (Austria); FNRS and FWO (Belgium); CNPq, CAPES, FAPERJ, and FAPESP (Brazil); MES (Bulgaria); CERN; CAS, MoST, and NSFC (China); COLCIENCIAS (Colombia); MSES (Croatia); RPF (Cyprus); Academy of Sciences and NICPB (Estonia); Academy of Finland, ME, and HIP (Finland); CEA and CNRS/IN2P3 (France); BMBF, DFG, and HGF (Germany); GSRT (Greece); OTKA and NKTH (Hungary); DAE and DST (India); IPM (Iran); SFI (Ireland); INFN (Italy); NRF and WCU (Korea); LAS (Lithuania); CINVESTAV, CONACYT, SEP, and UASLP-FAI (Mexico); PAEC (Pakistan); SCSR (Poland); FCT (Portugal); JINR (Armenia, Belarus, Georgia, Ukraine, Uzbekistan); MST and MAE (Russia); MSTD (Serbia); MICINN and CPAN (Spain); Swiss Funding Agencies (Switzerland); NSC (Taipei); TUBITAK and TAEK (Turkey); STFC (United Kingdom); DOE and NSF (USA)

The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA

PubMedID: 31604903Purpose: Amplifications of receptor tyrosine kinases (RTKS) are therapeutic targets in multiple tumor types (e.g. HER2 in breast cancer), and amplification of the chromosome 4 segment harboring the three RTKs KIT, PDGFRA, and KDR (4q12amp) may be similarly targetable. The presence of 4q12amp has been sporadically reported in small tumor specific series but a large-scale analysis is lacking. We assess the pan-cancer landscape of 4q12amp and provide early clinical support for the feasibility of targeting this amplicon. Experimental Design: Tumor specimens from 132,872 patients with advanced cancer were assayed with hybrid capture based comprehensive genomic profiling which assays 186–315 genes for all classes of genomic alterations, including amplifications. Baseline demographic data were abstracted, and presence of 4q12amp was defined as 6 or more copies of KIT/KDR/PDGFRA. Concurrent alterations and treatment outcomes with matched therapies were explored in a subset of cases. Results: Overall 0.65% of cases harbored 4q12amp at a median copy number of 10 (range 6–344). Among cancers with >100 cases in this series, glioblastomas, angiosarcomas, and osteosarcomas were enriched for 4q12amp at 4.7%, 4.8%, and 6.4%, respectively (all p < 0.001), giving an overall sarcoma (n = 6,885) incidence of 1.9%. Among 99 pulmonary adenocarcinoma cases harboring 4q12amp, 50 (50%) lacked any other known driver of NSLCC. Four index cases plus a previously reported case on treatment with empirical TKIs monotherapy had stable disease on average exceeding 20 months. Conclusion: We define 4q12amp as a significant event across the pan-cancer landscape, comparable to known pan-cancer targets such as NTRK and microsatellite instability, with notable enrichment in several cancers such as osteosarcoma where standard treatment is limited. The responses to available TKIs observed in index cases strongly suggest 4q12amp is a druggable oncogenic target across cancers that warrants a focused drug development strategy. Implications for Practice: Coamplification of the receptor tyrosine kinases (rtks) KIT/KDR/PDGFRA (4q12amp) is present broadly across cancers (0.65%), with enrichment in osteosarcoma and gliomas. Evidence for this amplicon having an oncogenic role is the mutual exclusivity of 4q12amp to other known drivers in 50% of pulmonary adenocarcinoma cases. Furthermore, preliminary clinical evidence for driver status comes from four index cases of patients empirically treated with commercially available tyrosine kinase inhibitors with activity against KIT/KDR/PDGFRA who had stable disease for 20 months on average. The sum of these lines of evidence suggests further clinical and preclinical investigation of 4q12amp is warranted as the possible basis for a pan-cancer drug development strategy. © 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.Orange Instituto Universitario de Tecnología Industrial de Asturias Comprehensive Cancer Center, City of Hope State University of New York City, University of London University of California, Irvine Rutgers Cancer Institute of New JerseyUmut Disel Russell Madison Kumar Abhishek Jon H. Chung Sally E. Trabucco Asli O. Matos Garrett M. Frampton Lee A. Albacker Venkataprasanth Reddy Nuri Karadurmus Adam Benson Jennifer Webster Semra Paydas Ruben Cabanillas Chaitali Nangia M.A. Ozturk Sherri Z. Millis Sumanta K. Pal Breelyn Wilky Ethan S. Sokol Laurie M. Gay Salil Soman Shridar Ganesan Katherine Janeway Phil J. Stephens Viola W. Zhu Sai-Hong Ignatius Ou Christine M. Lovly Mrinal Gounder Alexa B. Schrock Jeffrey S. Ross Vincent A. Miller Samuel J. Klempner Siraj M. Ali [email protected] Acibadem University, Acibadem Hospital Medical Oncology Adana Turkey Foundation Medicine, Inc. Cambridge Massachusetts USA Bon Secours Cancer Institute Richmond Virginia USA Saglik Bilimleri Universities Gülhane Tıp Fakültesi Ankara Turkey Department of Medical Oncology, Cukurova University School of Medicine Adana Turkey Instituto de Medicina Oncológica y Molecular de Asturias Asturias Spain Chao Family Comprehensive Cancer Center, University of California, Irvine School of Medicine Orange California USA Department of Medical Oncology, Marmara University School of Medicine Istanbul Turkey City of Hope National Medical Center Duarte California USA University of Miami School of Medicine Miami Florida USA Beth Israel Deaconess Medical Center Boston Massachusetts USA Cancer Institute of New Jersey New Brunswick New Jersey USA Boston Children's Hospital and Dana-Farber Cancer Institute Boston Massachusetts USA Vanderbilt Medical Center Nashville Tennessee USA Memorial Sloan Kettering Cancer Center New York New York USA SUNY Upstate Medical University Syracuse New York USA The Angeles Clinic and Research Institute Los Angeles California USA amplification tyrosine kinase inhibitor KIT PDGFRA genomic profiling sarcoma See http://www.TheOncologist.com for supplemental material available online. Supplemental Figures Supplemental Table